Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has issued an announcement.
Proteomics International Laboratories Ltd announced a planned transition in its Board and Management, with Managing Director Dr. Richard Lipscombe set to retire in February 2026, marking his 25th anniversary with the company. The transition aims to strengthen the company’s leadership as it continues to commercialize its world-class technology in precision diagnostics and precision medicine. A specialist biotechnology executive search firm has been appointed to find a new CEO with global experience in diagnostics, medical technology, and digital health commercialisation. Dr. Lipscombe will remain in his role until a successor is appointed, ensuring a smooth transition.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, is a medical technology company specializing in precision diagnostics and bio-analytical services. The company focuses on proteomics, which involves the large-scale study of proteins’ structure and function, aiming to enhance disease treatment through innovative tools.
Average Trading Volume: 357,716
Technical Sentiment Signal: Sell
Current Market Cap: A$49.92M
See more insights into PIQ stock on TipRanks’ Stock Analysis page.